In a significant step towards strengthening India’s fight against tuberculosis (TB), HaystackAnalytics has launched ‘TB One’, an indigenous solution aimed at enhancing TB diagnosis through Next-Generation Sequencing (NGS) in any diagnostic lab or hospital. This all-inclusive offering comprises a pre-sequencing kit for Whole Genome Sequencing (WGS), access to ‘Omega TB’—HaystackAnalytics’ proprietary clinical reporting software, and on-demand access to 2GB of sequencing data.
The Omega TB software generates a detailed clinical report covering resistance to 18 anti-TB drugs, detection of mixed infections, non-tuberculous mycobacteria (NTM), and heteroresistance—all within a single, standardized format. By providing healthcare professionals with precise, data-driven insights, ‘TB One’ aims to improve TB diagnosis and management, contributing to India’s efforts to combat the disease effectively.
This innovative solution was unveiled by Dr. Anirvan Chatterjee, Co-founder & CEO of HaystackAnalytics, and Dr. Rajendra Prasad at the Indian Council of Medical Research (ICMR)’s India Innovation Summit: Pioneering Solutions to End TB on March 19, 2025. Designed to make genomics-based TB testing more accessible and scalable, ‘TB One’ allows existing laboratories to upgrade to NGS-based TB testing without requiring major infrastructure changes. This aligns with HaystackAnalytics’ mission to make genomics-based diagnostics more accessible, practical, and cost-effective, helping molecular laboratories transition into advanced genomic testing facilities.
Speaking on the significance of ‘TB One’, Dr. Anirvan Chatterjee emphasized, “Our goal is to empower existing molecular labs with high-precision genomic testing without the need for expensive infrastructure upgrades. This scalable and cost-effective solution enhances accessibility to advanced TB diagnostics across India. Each TB One kit includes reagents to process 16 samples and requires prior extraction of TB DNA. It seamlessly integrates into existing molecular workflows, making TB genomic sequencing more efficient.”
Dr. Rajendra Prasad, a renowned pulmonologist with over 51 years of experience in TB research and care, stated, “Drug-resistant TB is one of the biggest challenges in TB management, and there is an urgent need for faster and more precise diagnostics. ‘TB One’ has the potential to revolutionize TB testing by enabling comprehensive drug resistance profiling in a single test—without requiring major lab upgrades. This could be a game-changer in TB care, ultimately saving countless lives. It marks an important step in India’s journey towards TB Mukt Bharat.”
